NewslettersNeural Cell NewsUncategorizeduniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s DiseaseBy Justin.choi - February 9, 2022014uniQure N.V. announced the dosing of the first two patients in its European open-label Phase Ib/II clinical trial of AMT-130, a potential one-time gene-therapy approach for the treatment of Huntington’s disease.[uniQure N.V.] 6445212 nan items 1 apa 0 default asc 1 171658 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/Press Release